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Abstract 
BACKGROUND: he achievement of optimal hypertension therapy requires cost-effective medicine. The treatment 
of hypertensive patients needs for long-term medication have made medical costs a prime issue in health 
economics. 
AIM: This study aims to determine the cost effectiveness of candesartan therapy compared to candesartan-
amlodipine therapy on hypertensive outpatients. 
METHODS: This is a prospective cohort study that compares candesartan therapy to candesartan-amlodipine 
therapy at a public hospital from payers’ perspective. The outcome is the percentage of targeted blood pressure 
decrease after three months of therapy. The cost effectiveness analysis uses the Incremental Cost Effectiveness 
Ratio (ICER) based on the ratio of cost difference to the outcome in both therapy groups. 
RESULTS: As many as 111 patients participated in this research, comprising 40 candesartan therapy patients 
and 71 patients with the combination of candesartan-amlodipine. Of the participants, 63.96% were female, 
57.66% were aged 60 or older, and 56.32% had diabetes mellitus as the most common complication. Results 
show that the average direct medical cost per patient for a therapy of three months with candesartan was IDR 
1,050,536 ± 730,007 and IDR 760,040 ± 614,290 for a candesartan-amlodipine therapy. The mean decline of 
systolic and diastolic blood pressure under candesartan therapy is less than that of candesartan-amlodipine, 
although without any significant difference (p > 0.05). It follows that the effectiveness of candesartan (85%) is 
greater than that of the candesartan-amlodipine combination (84.50%). Candesartan therapy is thereby more 
cost-effective with an ICER value of IDR 580,993/%. 
CONCLUSION: Hypertension therapy by candesartan is more cost-effective than candesartan-amlodipine 
therapy with a cost addition of IDR 580,993. 
 
 
 
 
 
Introduction 
 
The widely ranging prices of various 
antihypertension brands of angiotensin-converting-
enzyme inhibitors (ACEIs) and angiotensin receptor 
blockers (ARBs) play an important role in 
hypertension treatment management, particularly 
concerning comorbidities such as diabetes and heart 
failure. A health service provider has to be sensible in 
procuring drugs and determining the most effective 
cost according to the financial state of the patient so 
as to lessen the economic burden of the patient or the 
health care system [1]. The treatment of hypertensive 
patients (HTs) requires a long-term commitment of 
compliance for the patient and resources by the 
healthcare system. This poses an economic dilemma 
in countries where universal healthcare is standard [2] 
Candesartan is an angiotensin II receptor 
antagonist antihypertensive drug with a biphenyl 
derivative molecular structure. The active mechanism 
of candesartan inhibits the renin-angiotensin-
aldosterone system (RAAS) at level 1 of the 
angiotensin receptor (AT 1) for angiotensin II (AT II). 
In an RAAS reaction, AT II produces the strongest 
effect as vasoconstrictor. Candesartan reduces the 
adverse effects of angiotensin II endothelium by 
decreasing the release of vasoconstrictors which 
enhance arterial elasticity. Candesartan boasts its 
distinct advantage in increasing arterial elasticity when 
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compared to other conventional antihypertension 
medicine such as diuretics (Ds), β-blockers (BABs) 
and even calcium channel blockers (CCBs) [3]. 
A therapy with the combination of 
candesartan and amlodipine lowers the risk of major 
adverse cardiovascular events (MACEs) by 38% with 
a significant value of p = 0.025, compared to when the 
patients are simply treated with non-amlodipine and 
candesartan drugs [4]. 
Hypertension therapy takes a long time which 
consequently demands a great cost. The diverse 
effectiveness of antihypertensives and the broad price 
range of antihypertensive types also impact on the 
treatment cost. According to survey, candesartan or 
the combination of candesartan-amlodipine is the 
most common therapy or antihypertensive drug 
administered to hypertensive outpatients under the 
national health cover (JKN) at public hospitals. 
Considering this situation, research has been 
undertaken to examine the cost effectiveness of 
candesartan in comparison to candesartan-amlodipine 
in the medication of hypertensive outpatients. 
 
 
Material and Methods 
 
This study has gained ethical approval for 
research number 011802023 from the Research 
Ethics Committee of Universitas Ahmad Dahlan. The 
investigation employs a prospective cohort method 
comparing the outcome of candesartan therapy to that 
of candesartan-amlodipine at a public hospital from 
payers’ perspective. The cost effectiveness analysis 
utilizes the Incremental Cost Effectiveness Ratio 
(ICER) which is the ratio of cost difference to the 
outcome in both therapy groups. The calculated cost 
is the direct medical cost, or the average total therapy 
cost of hypertensive patients for three months. The 
assessed outcome is the targeted decline of blood 
pressure after three months of therapy, the proportion 
of patients with which is then counted against the total 
number of patients in each therapy group. 
Inclusion criteria: Outpatients diagnosed with 
hypertension (ICD10: I10), aged ≥ 18, male or female 
with or without another disease, consuming 
candesartan or candesartan-amlodipine 
antihypertensives, and listed as JKN / BPJS members 
Exclusion criteria: Patients who do not ingest 
the same drug during observations, do not undergo 
regular control, or have incomplete data of medical 
records, blood rates and costs. 
Beside using ICER, data analysis also 
identifies any notable difference in blood pressure 
decrease by t-test if the data are normally distributed, 
or by Mann-Whitney test if otherwise. 
Results  
 
Hypertensive outpatients who fulfilled the 
inclusion criteria amounted to 111 patients, consisting 
of 40 patients under candesartan therapy and 71 
patients under candesartan-amlodipine therapy. 
Detailed characteristics of the patients are described 
in Table 1. 
Table 1: Patient characteristics  
Characteristic N = 111 (%) 
Sex  
Male 40 36.04 
Female 71 63.96 
Age (years)   
< 60 47 42.34 
≥ 60 64 57.66 
Complication  
Arrhythmia 1 1.15 
CHF  3 3.45 
CAD 8 9.20 
CKD 3 3.45 
DM 49 56.32 
Dyslipidemia 4 4.60 
DM, Dyslipidemia 7 8.05 
Gerd 2 2.30 
OA  10 11.49 
Non-Complication 24 21.62 
CHF = Congestive Heart Failure; CAD = Chronic Artery Disease; CKD = Chronic Kidney 
Disease; DM = Diabetes Mellitus; Gerd = Gastro Esophageal; OA = Osteoarthritis. 
 
Therapy cost  
The therapy cost in this research is the total 
direct medical cost of hypertensive outpatients under 
the national health cover (payers’ perspective) 
receiving the antihypertensives candesartan and 
candesartan-amlodipine at a public hospital in 
Yogyakarta for three months from February to May 
2018. The cost components in this study are 
antihypertensive and non-antihypertensive drug cost, 
administration cost, laboratory cost, and medical 
examination cost. The mean direct medical cost of 
hypertensive outpatient therapy can be seen in Table 
2. 
Table 2. Average direct medical cost 
Therapy Average cost (IDR) p value 
Candesartan 1,050,536 ± 730,007 0.005 
Candesartan-Amlodipine 760,040 ± 614,290 
 
Table II depicts that the direct medical cost 
per patient for a three-month candesartan therapy 
amounts to IDR 1,050,536 ± 730,007, greater than 
that of the candesartan-amlodipine combination at 
IDR 760,040 ± 614,290. The huge standard deviation 
(SD) value stems from the sizeable range of the cost. 
The Mann-Whitney test indicates significant difference 
in the average total therapy cost between 
candesartan-amlodipine and candesartan with a p 
value of 0.005. 
 
Therapy effectiveness 
The effectiveness of candesartan and 
candesartan-amlodipine hypertension therapy is 
gauged by the decrease to the targeted blood 
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pressure based on the Evidence-Based Guideline for 
the Management of High Blood Pressure in Adults 
(JNC VIII), as can be observed in Table 3. 
Table 3. Therapy effectiveness 
Average blood 
pressure decrease 
Candesartan 
Candesartan- 
Amlodipine 
p value 
p value 
(RR;95%CI) 
Systole (mm/Hg) 8.50 13.24 0.259  
Diastole (mm/Hg) 5.25 5.92 0.645  
Effectiveness (%) 85.00 84.50  
1.000 
(1.006;0.854-1.185) 
 
It transpires that the effectiveness of 
candesartan therapy for hypertensive outpatients in 
terms of average systolic blood pressure decline at 
8.50 mm/Hg is less than that of candesartan-
amlodipine at 13.24 mm/Hg. However, the Mann-
Whitney test discerns no substantial distinction 
between candesartan and candesartan-amlodipine in 
this respect as p = 0.259. Similarly, the diastolic blood 
pressure reduction in the candesartan therapy (5.25 
mm/Hg) is lower than that in the candesartan-
amlodipine treatment (5.92 mm/Hg), but no 
meaningful disparity emerges from The Mann-Whitney 
test either (p = 0.645). 
The therapy effectiveness measured in this 
study, which is subsequently taken into account in the 
cost effectiveness analysis, is presented as the 
percentage of blood pressure loss according to target 
after three months of therapy. Table III points out that 
the therapy effectiveness of candesartan (85.00%) is 
greater than that of candesartan-amlodipine (84.50%). 
 
Cost effectiveness analysis 
The cost effectiveness analysis of 
hypertension therapy in this research is done by 
ICER, which is the difference between cost and 
effectiveness in each hypertension therapy group, 
obtained by comparing the total cost to be directly 
spent with the output, which is the effective 
percentage of targeted blood pressure decrease after 
three months of therapy with candesartan and 
candesartan-amlodipine antihypertensives. The ICER 
value of hypertensive outpatients treated with 
candesartan and candesartan-amlodipine is featured 
in Table 4. 
Table 4. Therapy cost effectiveness 
Therapy Average cost (IDR) 
Therapy 
effectiveness (%) 
ICER value 
(IDR/%) 
Candesartan 1,050,536 ± 730,007 85.00 
580,993 
Candesartan-Amlodipine 760,040 ± 614,290 84.50 
 
It is notable from Table IV that the ICER value 
stands at IDR 580,993/%, signifying that hypertension 
therapy by candesartan is more cost-effective by IDR 
580,993 for every percent. 
 
 
 
Discussion 
 
Descriptive analysis of patient characteristics 
in this study reveals that the incidence rate of 
hypertension in female patients is greater than in their 
male counterparts and is 57.66% higher in patients 
aged 60 or above than in those under 60 years old. 
Following menopause, ceased production of 
endogenous estrogens prevents the female body from 
maintaining vasodilatation that controls blood 
pressure, thus causing the high prevalence of 
hypertension in women [5]. 
Other diseases, including chronic ones, that 
potentially exacerbate organ damage due to 
hypertension may occur as comorbidities or 
complications. Among patients in this research, the 
most frequent is diabetes mellitus (DM) at 56.32%. In 
DM type 2 patients, high insulin levels can accelerate 
the production of corticotrophin and cortisol hormones 
by the reins, which in turn triggers neurological stress 
that leads to rising blood pressure in the arteries. It 
can be stated that DM and hypertension have a linear 
relationship [6]. 
On average, the direct medical cost of 
candesartan therapy administered to a patient for 
three months is significantly higher than that of 
candesartan-amlodipine at p = 0.005. In this case, the 
mean total direct cost of a 3-month candesartan-
amlodipine therapy is IDR 760,040 ± 614,290. 
Compared to other research [7] in which the average 
monthly cost of candesartan-amlodipine 
antihypertensives given to hypertensive patients with 
comorbidities varies between IDR 167,700 and IDR 
200,280, this study found that the mean total cost 
ranges from IDR 297,667 to IDR 878,479 per month, 
affected by the cost of antihypertensives (p < 0.001), 
non-antihypertensives (p < 0.001), and the treatment 
of comorbidities (p = 0.001). 
On the other hand, therapy by candesartan is 
less effective than by the combination of candesartan-
amlodipine in terms of systolic and diastolic blood 
pressure reduction, but the Mann-Whitney test does 
not indicate any marked difference between both. 
Nevertheless, in regard to achieving the targeted 
blood pressure loss after three months, the 
effectiveness of candesartan therapy is superior to 
that of candesartan-amlodipine, although not 
significant difference RR = 1,006 (0.854-1.185). In 
comparison, another study [8] shows considerable 
decline of systolic and diastolic blood pressure 
following four and eight weeks of candesartan and 
amlodipine therapy respectively, although amlodipine 
and candesartan are not meaningfully dissimilar in 
reducing blood pressure in this context. 
All in all, according to the resulting ICER, 
hypertensive therapy by candesartan is more cost-
effective than by candesartan-amlodipine with a 
difference of IDR 580,993. To compare with, prior 
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research [9] divulges that hypertension therapy by 
combined candesartan-amlodipine is firmly more cost-
effective than by candesartan-diltiazem with an ICER 
of IDR -23,187.40/%. 
In conclusion, hypertension therapy by 
candesartan is more cost-effective than by 
candesartan-amlodipine with an ICER value of IDR 
580,993/%. 
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